drugset / Trial / NCT02534506
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.
Timeline
- Start
- 2015-11-06
- Primary completion
- 2016-11-11
- Completion
- 2016-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Urelumab | Monoclonal antibody | — | Intravenous |
| Background | Nivolumab | Monoclonal antibody | — | Intravenous |